Valeant Pharmaceuticals Intl Inc(NYSE:VRX) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Aug 9, 2016. Company reported revenue of $2.42B. Analysts estimated a revenue of $2.46B. Earnings per share were $1.40. Analysts had estimated an EPS of $1.48.
In a different note, BMO Capital said it Initiates Coverage on Valeant Pharmaceuticals Intl Inc, according to a research note issued on Jun 29, 2016. The shares have been rated ‘Market Perform’ by the firm. On Jun 23, 2016, JP Morgan said it Downgrades its rating on Valeant Pharmaceuticals Intl Inc. In the research note, the firm Lowers the price-target to $50.00 per share. The shares have been rated ‘Neutral’ by the firm. On Jun 8, 2016, Jefferies said it Maintains its rating on Valeant Pharmaceuticals Intl Inc. In the research note, the firm Lowers the price-target to $53.00 per share. The shares have been rated ‘Buy’ by the firm. On Jun 8, 2016, Stifel Nicolaus said it Maintains its rating on Valeant Pharmaceuticals Intl Inc. In the research note, the firm Lowers the price-target to $65.00 per share. The shares have been rated ‘Buy’ by the firm.
Valeant Pharmaceuticals Intl Inc (VRX) made into the market gainers list on Wednesdays trading session with the shares advancing 12.78% or 3.4 points. Due to strong positive momentum, the stock ended at $30, which is also near the day’s high of $30.59. The stock began the session at $29.11 and the volume stood at 8,12,38,338 shares. The 52-week high of the shares is $252.51 and the 52 week low is $18.55. The company has a current market capitalization of $10,426 M and it has 34,75,35,490 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Jun 27, 2016, Thomas W. Sr. Ross (director) purchased 4,000 shares at $24.40 per share price.Also, On Jun 13, 2016, Joseph C Papa (CEO) purchased 202,000 shares at $24.48 per share price.On Nov 9, 2015, J. Michael Pearson (Chief Executive Officer) sold 1,297,399 shares at $78.53 per share price, according to the Form-4 filing with the securities and exchange commission.
Valeant Pharmaceuticals International Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing manufacturing and marketing a range of branded generic and branded generic pharmaceuticals over-the-counter (OTC) products and medical devices (contact lenses intraocular lenses ophthalmic surgical equipment and aesthetics devices) which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Company’s developed markets segment consists of sales in the United States of pharmaceutical products OTC products and medical device products. The Company’s Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals OTC products and medical device products.